Aevi Genomic Medicine, Inc. GNMX Cash Flow

Aevi genomic medicine, inc. (GNMX)

CashFlow / TTM

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
-19,152	-22,359	-26,905	-30,775	-31,308	-32,664	-32,506	-34,714	-36,038	-38,003	-41,677	-41,904	-39,884	-45,835	-40,214	-37,992	-37,725	-24,244	-21,998	-18,433	-17,445	-20,548	-18,807	-17,129	-14,307	-11,191	-16,038	-15,071	-14,696	-15,093	-10,470	-8,096	0	0	0
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation
35	52	65	65	65	63	87	112	134	224	251	268	289	241	255	240	244	251	224	225	209	191	182	177	167	157	149	145	141	134	116	98	0	0	0
Loss from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Stock-based compensation
1,942	2,439	2,969	3,090	3,003	3,128	3,116	3,368	3,251	4,300	5,389	6,788	7,737	7,611	8,471	9,188	8,957	8,520	7,555	6,202	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of warrants classified as a liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,370	1,359	-641	379	-585	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	269	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Exchange differences on a restricted lease deposit and on long term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	4	-18	5	-6	-5	-4	-4	0	0	0
Loss from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Issuance of shares as consideration for providing security for letter of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Stock-based compensation related to options, warrants, common shares and restricted shares granted to employees, directors and consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	2,320	2,131	484	395	0	0	0
Interest and amortization of beneficial conversion feature of convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Change in fair value of convertible debentures and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-2,978	-3,260	-545	1,936	0	0	0
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-135	-283	-151	-723	-416	-220	-180	558	365	-20	194	-412	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-99	-104	-180	-79	0	0	0
Restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-3	-2	-5	-4	-5	0	0	0	-	-	-	-
Accounts receivable and prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-499	-821	37	-360	407	133	-1,237	-543	0	0	0	-	-	-	-
Exchange differences on a long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Decrease (increase) in accounts receivable and prepaid expenses and deferred issuance expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Exchange differences on a restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Exchange differences on a long term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Trade payables
-1,462	-1,161	-949	639	-1,896	-418	-1,115	806	2,863	1,378	1,459	-1,185	-813	-239	854	246	879	-246	-392	14	-994	87	-72	185	776	-17	54	-26	-158	653	483	764	0	0	0
Other accounts payable and accrued expenses
-720	-93	102	-434	2,256	444	404	-2,249	-2,278	-253	464	2,860	-3,662	1,445	1,193	24	6,162	117	-1,169	610	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Restricted lease deposits
-	-	-	-	-	-	-	-	-	-	-	-12	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long term assets
0	0	-33	-43	0	0	33	43	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-25,312	-	-20,483	-17,152	-16,349	-12,195	-12,967	-13,227	-13,916	-12,732	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-19,222	-20,839	-24,534	-26,649	-27,464	-29,195	-29,835	-33,246	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
-	-	0	-	-	-	0	-	-	31	157	221	334	277	233	187	188	231	358	364	316	277	173	186	168	160	64	63	93	163	280	289	0	0	0
Proceeds from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-233	-	-187	-230	-357	-363	-313	-274	-170	-183	0	0	0	-	-	-	-	-	-	-	-
Increase in restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net cash provided by (used in) investing activities
0	0	0	0	-4	148	148	148	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,861	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of shares and warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Deferred issuance expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Proceeds from issuance of shares and warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from exercise of options and warrants
0	0	0	34	34	34	34	19	38	128	200	181	162	1,040	1,396	1,428	1,443	753	512	1,244	1,229	951	764	13	199	1,696	1,724	1,711	1,550	53	25	63	0	0	0
Repayment of a long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Proceeds from long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Issuance of a convertible debenture and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	44,278	-	23,689	22,965	22,724	23,456	1,195	951	764	28,874	0	0	0	-	-	-	-	-	-	-	-
Increase in short-term bank credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by financing activities
2,001	5,125	4,962	4,996	32,110	26,841	27,004	26,989	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Decrease in cash and cash equivalents
-	-	-19,572	-	-	-	-2,683	-6,109	-32,297	-32,329	-14,689	-13,226	29,532	31,674	18,733	19,776	3,019	5,583	6,018	10,898	-12,085	-12,550	-13,322	15,959	17,792	19,939	29,870	1,436	1,429	-1,076	1,247	2,136	0	0	0
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	14	49	0	0	0
Cash paid during the period for taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	15	11	8	12	20	18	-24	17	15	24	86	50	40	32	11	1	0	0	0
Receivables resulting from the exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance expenses paid with shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	0	0	0	0	0
Issuance of Common stock upon conversion of a convertible debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	8	8	5,585	5,585	0	0	0
Issuance of Common stock and warrants to consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Classification of liability in respect of warrants into equity due to the exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	883	883	1,035	386	398	1,131	0	0	0